SynthesisFrontiers in oncology2026
A meta-analysis and expression profiling of DNA repair gene polymorphisms in leukemia.
Synthesis in Frontiers in oncology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Genetic susceptibility is believed to contribute to leukemia development. This study aimed to systematically evaluate the association between DNA repair gene polymorphisms, particularly xeroderma pigmentosum (XP) and excision repair cross-complementing (XRCC) genes, and leukemia risk. Methods: A comprehensive search of PubMed, Web of Science, Scopus, and Cochrane Library was conducted until December 3, 2025, concerning the association between DNA repair gene polymorphisms and leukemia risk. Gene expressions were performed in Leukemia DB, GEPIA2, and BloodSpot datasets. Results: Fifty-four studies were included in the meta-analysis. No significant associations were observed for ERCC1 C118T or XPD Asp312Asn across genetic models, whereas ERCC1 8092C>A showed significant associations in homozygous and dominant models. The XPD Lys751Gln polymorphism demonstrated significant associations across all models. Significant associations were identified for XPC Lys939Gln in allelic, homozygous, and recessive models and for XPF Arg415Gln in the heterozygous model. XPG 3507G>C showed no significant association. XRCC1 Arg194Trp, XRCC1 Arg399Gln, and XRCC3 Thr241Met polymorphisms were significantly associated with leukemia risk, while XRCC1 Arg280His was not. Gene expression analyses revealed subtype-specific alterations in DNA repair genes across leukemia datasets. Conclusions: Several DNA repair polymorphisms, including
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.